As measles cases continue to climb across the United States and globally, NanoViricides, Inc. (NYSE American: NNVC) is advancing its investigational antiviral NV-387 toward a Phase II clinical trial for the treatment of measles. The company has announced that it is developing a clinical trial protocol and intends to submit it to the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) process. This move comes at a critical time when public health officials are grappling with resurgent measles outbreaks, underscoring the need for effective therapeutic interventions.
NV-387 has already demonstrated strong in vivo activity against lethal measles infection in a humanized animal model, according to the company. Moreover, the FDA has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Drug (RPDD) Designation for NV-387 as a measles treatment. The RPDD designation is particularly notable because it could make NanoViricides eligible for a Priority Review Voucher (PRV) upon approval of a qualifying marketing application, provided all applicable requirements are met. PRVs are transferable and can be sold, potentially providing significant financial upside.
The push toward clinical trials for measles comes as the world witnesses a troubling rise in cases. The Centers for Disease Control and Prevention (CDC) has reported outbreaks in multiple states, and the World Health Organization has noted a global increase in measles incidence. While vaccination remains the primary prevention strategy, there is a clear unmet medical need for antiviral treatments, especially for immunocompromised patients and those who contract the virus despite vaccination. NanoViricides' host-mimetic nanomedicine technology aims to address this gap by creating broad-spectrum antivirals that mimic host cell receptors to attract and neutralize viruses.
"We are encouraged by the progress of NV-387 and the regulatory momentum," said a company spokesperson. "The rise in measles cases highlights the urgency of developing effective treatments, and we are committed to moving NV-387 into human trials as efficiently as possible." The company plans to engage with the FDA to refine the Phase II protocol, which will evaluate the safety and efficacy of NV-387 in patients with measles.
The implications of this development are significant. If NV-387 proves successful in clinical trials, it would offer the first antiviral treatment specifically for measles, which currently has no approved antiviral therapy. This could transform patient management, reduce hospitalizations, and curb the spread of the virus. Additionally, the potential PRV from the RPDD designation adds a strategic financial dimension, as these vouchers have historically been sold for hundreds of millions of dollars.
For NanoViricides, this program is part of a broader pipeline that includes NV-387 as a broad-spectrum candidate for other respiratory infections like RSV, COVID-19, and influenza, as well as other viral diseases. The company is also developing NV-HHV-1 for shingles. However, the company acknowledges the inherent uncertainties in drug development, noting that there can be no assurance that any candidate will achieve successful clinical results or regulatory approval.
As the world watches the measles resurgence, the advancement of NV-387 toward Phase II trials represents a beacon of hope. It underscores the importance of continued investment in antiviral research and development. With the FDA designations and promising preclinical data, NanoViricides is well-positioned to make a meaningful impact in the fight against measles.
